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Background
The introduction of novel, fixed NRTI combinations
(emtricitabine-tenofovir, E-T, and lamivudine-abacavir,
L-A), expanded the available spectrum of antiretroviral
formulations, and indirectly increased patient’s adher-
ence, since both these combinations are taken as a one
pill-once daily regimen.
Methods
A prospective survey of the use of these two fixed NRTI
combinations was performed in our cohort of over
1,700 HIV-infected patients (p).
Results
During 12 consecutive months, 334 p received for the first
time E-T (262 cases), or L-A (72 p). Among the 88 p naïve
to all antiretrovirals, E-T was given to 66 p (75.0%), mostly
associated with efavirenz (51 p), or different PI combina-
tions (15 p), whereas L-A was administered to 22 p only
(in 18 of them in association with PI). In the remaining
246 p, E-T or L-A therapy replaced a prior regimen, pre-
dominantly associated with PI (141 cases p), versus efavir-
enz (48 p), or oher combinations (57 p). Among the 246
pre-treated p, E-T (194 p), still prevailed over L-A (50 p),
and the therapeutic change was due to failure and resis-
tance (89 p), and in the majority of cases to toxicity or
poor tolerability (146 p). Both fixed NRTI combinations
were well tolerated, with only three cases of L-A suspen-
sion due to abacavir hypersensitivity, and two cases of E-T
interruption due to kidney abnormalities.
Discussion
From our preliminary experience, a major role seems
played by E-T in first-line treatments (preferably among
“compact” regimens based on efavirenz), while the appar-
ently increased L-A prescription to pre-treated p is attri-
butable to the different genetic barrier of abacavir (which
is often introduced in association with PI). The present
availability to two more fixed NRTI combinations advan-
taged by once-daily administration strongly encourages
further “head to head” studies in both first-line and
experienced p, in order to better exploit and target their
therapeutic potential and their convenience features.
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